Meredith Ian T
Known title: EVP Global Chief Med OfficerCIK: 0001693920
Associated companies
Transaction History
| BSX | ▼ Sell | Open Market | 6,588 | $288K | 3/28/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 300 | $13K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,019 | $0 | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,013 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 298 | $13K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,037 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 305 | $13K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,250 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 367 | $16K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,108 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 326 | $14K | 2/15/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 3,131 | $0 | 2/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 919 | $40K | 2/1/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 3,649 | $0 | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 1,265 | $54K | 1/1/2022 | View on chart |
| BSX | ▼ Sell | Open Market | 7,018 | $303K | 12/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.